All the latest news and updates from Medovate.
23rd September, 2021
Ground-breaking regional anaesthesia device, SAFIRA®, invented by clinicians at The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust (QEH) and developed in conjunction with Medovate, has been awarded ‘Patient Safety Innovation of the Year’ at this year’s HSJ Patient Safety Awards.
24th August, 2021
Medovate is pleased to announce that Jim Beyer is joining the team as US Commercial Executive Consultant to focus on positioning Medovate’s FDA cleared device SAFIRA™ (Safer Injection for Regional Anesthesia) throughout the United States to both national and regional Group Purchasing Organizations (GPO’s) and Integrated Delivery Networks (IDN’s).
16th August, 2021
Medovate announces it has successfully secured additional CE Mark Regulatory Approvals for its game-changing SAFIRA® (SAFer Injection for Regional Anaesthesia) technology to include an NRFit™ syringe and a Palm Operator.
22nd July, 2021
A team from Medovate will be amongst hundreds of relay runners taking on the iconic Chariots of Fire Charity Relay event this year in September. Chariots of Fire is one of Cambridgeshire’s largest annual charity events. Organised and managed by Hewitsons Charitable Trust, the event will see teams of six each run a 1.7 miles course in relay format.
12th July, 2021
Medovate and its Australian distributor, LTR Medical, have signed an agreement which will allow LTR Medical to assess the potential for distribution of SAFIRA™ for veterinary use across Australia and New Zealand.
28th June, 2021
A pioneering regional anaesthesia device, invented by clinicians at Queen Elizabeth Hospital Kings Lynn NHS Trust (QEH) and developed in conjunction with medical device company Medovate, has been shortlisted for ‘Patient Safety Innovation of the Year’ at this year’s HSJ Patient Safety Awards.
24th June, 2021
Medovate are delighted to be named as Headline Sponsor for the Medipex NHS Innovation Awards 2021
22nd June, 2021
Medovate has been named “Best Medical Device Innovation Development Company 2021 – UK” for its collaboration, determination and enthusiasm to support the development of NHS-created innovation.
18th June, 2021
Medovate is delighted to be partnering with Markomed to evaluate SAFIRA® (SAFer Injection for Regional Anaesthesia) in Croatia.
Evaluations of SAFIRA™ will take place at the University Hospital Centre Zagreb and will assess SAFIRA™’s clinical performance and collate feedback from clinicians.
9th June, 2021
A male lion at Five Sisters Zoo (FSZ) in West Calder in Scotland has become the first animal in the world to have dental surgery using a revolutionary regional anaesthesia device, SAFIRA®, developed by NHS clinicians.
The lion was confiscated from a travelling circus in Belgium where he had been mistreated. The lion has been successfully re-homed at FSZ where the expert team have led his rehabilitation so he can now live a happier life.
23rd May, 2021
One of the fast-growing companies in the country, Omneya Medical Co’s vision is to bring novel innovations to medical systems that support improvements in patient safety and care, a philosophy that aligns well with Medovate and the foundations on which SAFIRA™ was developed.
11th May, 2021
Building on their existing partnership to promote ultrasound-guided regional anaesthesia Medovate and Konica Minolta Healthcare Americas Inc will showcase their combined solution and sponsor educational and training sessions at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 46th Annual Meeting.
21st April, 2021
Medovate are delighted to be a Silver Sponsor of the RA-UK Annual Scientific Meeting 2021, which is taking place on Wednesday 5th – Thursday 6th May 2021. Regional Anaesthesia - UK (RA-UK) have announced that, due to ongoing coronavirus restrictions, the event this year will be delivered virtually in a dynamic format. The two-day conference will be filmed in a TV style production and broadcast live from a venue in Sheffield.
19th April, 2021
Medovate’s recent e-ESRA congress symposium ‘Mitigating for Nerve Injury by Innovation’ was a reminder that both improvements in patient safety and total cost optimisation are important considerations when introducing new technology to regional anaesthesia (RA). Sales and Marketing Director at Medovate, Chris Rogers looks at the key symposium takeaways.
6th April, 2021
Medovate is delighted to be partnering with Pharmamed to evaluate SAFIRA® (SAFer Injection for Regional Anaesthesia) in one of the largest healthcare institutions in Slovenia.
4th March, 2021
Medovate is partnering with its UK distributor Vygon Vet to introduce its game-changing anaesthesia device SAFIRA® to veterinary practice.
26th February, 2021
Medovate are pleased to be a gold sponsor at this year’s ESRA (European Society of Regional Anaesthesia & Pain Therapy) e-Congress taking place on Saturday 13th March 2021.
22nd February, 2021
Medovate is delighted to be featured on the UK Healthcare Pavilion – the first ever UK-wide portal to showcase the UK healthcare and life sciences industry.
19th February, 2021
A new study examining the performance of Medovate’s novel HME safety device in simulated clinical settings confirms proof of principle of the HUMIDICARE® engineered device. The novel HME provides warning of the error of dual humidification in a mechanical ventilation circuit.
28th January, 2021
Medovate has announced a newly formed partnership with Konica Minolta Healthcare Americas, Inc. to promote best practice within regional anaesthesia across the United States and the Middle East.
6th January, 2021
Medovate are pleased to announce that we will be supporting as a Bronze Sponsor the Winter Scientific Meeting 2021 (WSM 2021), which is being held as a fully virtual event for the very first time on Wednesday 13th – Thursday 14th January 2021.
Hosted by the Association of Anaesthetists, the event is the UK's biggest annual anaesthetic and peri-operative medicine conference.
18th December, 2020
Chris Rogers, Sales & Marketing Director at Medovate shared a review of 2020 from Medovate's perspective on LinkedIn - read it here.
17th December, 2020
The Medovate Offices will be closed from 12 noon on Thursday, 24th December and will re-open on Monday 4th January 2021.
15th December, 2020
Medovate is proud to announce conclusion of an agreement with Mercury Medical to distribute its medical device SAFIRA™ (SAFer Injection for Regional Anesthesia) – a move that will now provide 100% coverage across the United States of America.
9th December, 2020
Medovate and its Brisbane-based distributor LTR Medical have announced they have secured both TGA (Therapeutic Goods Administration) Approval in Australia and inclusion on the WAND Database in New Zealand for their game-changing SAFIRA™ (SAFer Injection for Regional Anaesthesia) technology.
25th November, 2020
Medovate's game-changing medical device SAFIRA® (SAFer Injection for Regional Anaesthesia) named "Best Regional Anaesthesia Safety Solution 2020" in the GHP Healthcare and Pharmaceutical Awards
3rd November, 2020
Medovate signs an exclusive agreement with Sela Medical Ltd to distribute SAFIRA™ (SAFer Injection for Regional Anaesthesia) across Israel.
19th October, 2020
Medovate and Vygon Group announce that they have signed an exclusive deal to distribute SAFIRA® (SAFer Injection for Regional Anaesthesia) across 60 countries. Vygon will start a phased launch of SAFIRA in Europe at the end of 2020, with other global markets to follow.
28th September, 2020
Medovate’s game-changing SAFIRA® (SAFer Injection for Regional Anesthesia) has been featured in the Journal of Anaesthesia Practice.
The article, written by Dr Stewart Southey, looks at how the COVID-19 pandemic has challenged the very nature of anaesthesia services, and the need for increased attention on patient safety in regional anaesthesia.
15th September, 2020
Medovate – a pioneering medical device development company specialising in anaesthesia, airway management, critical care, and surgery – announced it has received CE Mark Approval for its game-changing medical device SAFIRA® (SAFer Injection for Regional Anaesthesia).
8th September, 2020
Medovate has concluded a distribution agreement with Brisbane-based LTR Medical which will provide exclusivity for SAFIRA® in Australia and New Zealand.
1st September, 2020
Cambridge-based medical device company Medovate has been named ‘2020’s Leading Innovators in Medical Device Development’ in Global Health & Pharma’s (GHP) 2020 Global Excellence Awards.
11th August, 2020
Face masks designed by Medovate and donated to a motor sport medical response unit have been used at the 70th Anniversary British Grand Prix.
29th July, 2020
Medovate has concluded an agreement with Iowa based TLC Medical to act as an additional exclusive distributor for its FDA cleared SAFIRA™ (SAFer Injection for Regional Anaesthesia) innovation in the United States of America.
16th July, 2020
Medovate are supporting two winning entries from the latest Health Enterprise East Innovation Voucher Competition.
Both winning entries have come from clinicians working at the West Hertfordshire Hospitals NHS Trust; Consultant Anaesthetists, Dr. Beena Parker and Dr. Rajesh Shankar.
8th July, 2020
Medical device company Medovate Ltd, is the first business to answer the call to donate to a new fund to support NHS innovation.
22nd June, 2020
Medical device company Medovate Ltd has announced achieving successful grant of a UK patent for their HUMIDICARE® technology.
2nd June, 2020
Medovate has announced that they will be partnering with the New York School of Regional Anesthesia (NYSORA) to support the launch of SAFIRA™, their innovation for regional anesthesia in the United States.
30th April, 2020
Medovate is developing an innovative face mask incorporating a specialised filter which has been proven to be an effective barrier against viruses.
14th April, 2020
Medovate has concluded agreements with three USA-based companies to act as the exclusive distributors for its innovative medical technology for regional anaesthesia, SAFIRA (Safer Injection for Regional Anaesthesia) across the United States of America.
9th April, 2020
Medovate are working with healthcare marketing communication specialists Onyx Health to prepare for the upcoming launch of their revolutionary SAFIRA technology for regional anaesthesia in the United States.
23rd March, 2020
Medovate has secured the exclusive rights to bring to market a pioneering endoscopic surgical device.
The new device, ENDOVAC, has the potential to dramatically improve survival of patients with life threatening infection following a leak from their the upper gastrointestinal (GI) tract whilst significantly enhancing current treatment methods.
19th March, 2020
During the current situation concerning the COVID-19 pandemic, we would like to reassure you that you can continue to contact Medovate as normal as our team are working from home.
Click to read full details of how we are remaining operational and how to contact the Medovate team during this time.
4th February, 2020
Medovate is breaking into the US market with the launch of the FDA approved SAFIRA regional anaesthesia innovation, at ASRA 2020 (the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting), taking place in San Francisco on the 23rd - 25th April. In addition to this, Medovate has also joined the Association of British Healthcare Industries (ABHI) US Accelerator.
29th November, 2019
Exactly two years since launch, Medovate, the medical device development company, is excited to be moving into its next chapter of growth with a relocation that will increase its capacity dramatically.
11th October, 2019
Medovate, the medical device development company, is pleased to announce the appointment of Chris Rogers as its new Sales and Marketing Director.
4th October, 2019
Medovate will be exhibiting and sponsoring a workshop session at the second World Airway Management Meeting (WAMM) taking place at the Amsterdam Conference Centre Beurs van Berlage on 13th – 16th November 2019 as an official Executive Partner of the event.
Medovate will be showcasing two exciting innovative medical technologies at Medica 2019 in Düsseldorf on 18 - 21 November 2019.
24th September, 2019
Medovate, the Cambridge-based medical device company has been named ‘Most Innovative Medical Device Development Company’ in Eastern England in Global Health & Pharma’s (GHP) 2019 Healthcare and Pharmaceutical Awards.
6th June, 2019
Medovate is developing two new medical devices to improve patient safety and reduce the risk of nerve damage during regional anaesthesia procedures. As part of the process they have engaged the services of a leading manufacturer of educational tools for ultrasound guided interventional procedures to complete comprehensive simulated usability testing.
8th May, 2019
Medical device company, Medovate, has secured the exclusive rights to develop and market an innovative safety Heat and Moisture Exchanger (HME), a life-saving breathing apparatus designed to prevent critical airway obstruction, a medical ‘never event’.
2nd April, 2019
Medovate, the medical device company, has today announced it has achieved ISO 13485:2016 quality management system certification.
5th February, 2019
Medical device development company, Medovate, has today announced that it has secured the exclusive rights to design, develop, and manufacture Arterial Glucosave, a pioneering life-saving solution for arterial line procedures.
10th December, 2018
Dedicated to the development and commercialisation of medical technologies, Medovate is pleased to announce it has secured the exclusive rights to design, develop, manufacture and sell two ground-breaking innovations in the field of anaesthesia.
20th November, 2018
Recently held at the Wellcome Trust, Genome Campus, Hinxton Hall, Cambridge, Medovate were pleased to support the Medtech Futures conference hosted by Health Enterprise East, (HEE).
Sign up to receive relevant news, updates and insights
Details of appointed distributors can be viewed by clicking here.
Medovate are in the process of appointing further distributors.
Find out about Distributor Opportunities here.
© 2021 Medovate. All Rights Reserved.